Healius Limited
ASX: HLS
Revenue momentum and diagnostics mix gains support HLS’s Pathology turnaround and margin recovery.
(Source: TradingView) 3-Month Performance Profile of HLS on a DTF compared to S&P/ASX 200 (XJO).
Healius (HLS) delivered FY25 group revenue growth of 5.7% to $1.34 billion, reflecting improved Pathology momentum post the Lumus sale and a sharp
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
